Evidence map›Paper›PMID 40746858›Full record

ArticleFrontiers in cell and developmental biology2025

Profiling the impact of different tau species on glial cell biology.

Ines Arribas Gomez, Yan Yan, Meredith T Lilley, Yunfei Chen, Lillian M Daughrity, Ana Moreno Arnas, Ji Shi, Jennifer M Kachergus, E Aubrey Thompson, Karen Jansen-West and 1 more

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ines Arribas GomezDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
Yan YanDivision of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States.
Meredith T LilleyNeuroscience Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Jacksonville, FL, United States.
Yunfei ChenDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
Lillian M DaughrityDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
Ana Moreno ArnasDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
Ji ShiDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, United States.
Jennifer M KachergusDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, United States.
E Aubrey ThompsonDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, United States.
Karen Jansen-WestDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
Casey N CookDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.

Funding

Mechanistic insights into the link between the A152T risk variant and tauopathyR01AG063780 · NIA · MAYO CLINIC JACKSONVILLE · PI COOK, CASEY N · 2020 to 2024
$2.5M
Impact of T cells on the CNS during aging and Alzheimer’s diseaseR01AG065219 · NIA · MAYO CLINIC JACKSONVILLE · PI COOK, CASEY N · 2020 to 2024
$2.4M
Investigating tau and ApoE4-mediated alterations in oligodendrocyte progenitor cellsR01AG071513 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI Casey N Cook · 2022 to 2026
$2.3M
NIA NIH HHS R01 AG063780NIA NIH HHS R01 AG065219NIA NIH HHS R01 AG071513
6 · The paper itself

Abstract

Introduction: Tauopathies are a heterogeneous group of neurodegenerative disorders characterized by abnormal tau protein accumulation in neuronal and/or glial cells. Different pathogenic tau mutations result in distinct patterns of tau deposition, yet the differential effects of these tau species on glial cell biology are poorly understood. This study examines glial cell function in response to two distinct tau variants: P301L (promoting insoluble/fibrillar tau) and A152T (favoring soluble/oligomeric tau). Methods: We used adeno-associated virus to express human tau containing either the P301L or A152T mutation and delivered to the brain by intracerebroventricular injection on postnatal day 0. At 3 months of age, we used the nCounter mouse glial profiling panel to measure expression of 770 genes involved in glial cell biology in the brain. Differential expression and pathway analysis, as well as cell type profiling were performed to assess how glial cell signatures in P301L-AAV and A152T-AAV mice differ in comparison to the control group (GFP-AAV injected mice). Results: P301L-AAV and A152T-AAV mice exhibited both common and distinct changes in their glial gene expression profiles. P301L-AAV mice showed a pronounced microglial inflammatory response with upregulation of microglial activation markers (Clec7a, Cst7, Gpr84) and inflammatory mediators (Ccl3, Nlrp3). A152T-AAV mice demonstrated a more prominent astrocytic response with upregulation of astrocyte-specific genes (Gdpd2, Ggta1, Aqp4, Fbln5). In addition, only A152T-AAV mice exhibited coordinated impairment in glucose metabolism, mitochondrial function, calcium signaling, protein clearance, and increased apoptotic signaling. Discussion: Our findings reveal that different patterns of tau accumulation elicit fundamentally distinct glial responses. Insoluble tau deposition (P301L) primarily triggers microglial inflammatory pathways without substantial metabolic disruption, suggesting a direct response to tau fibrils. In contrast, soluble tau species (A152T) impact multiple cellular mechanisms simultaneously, including metabolic function, calcium homeostasis, and phagocytosis, potentially explaining the neuronal loss previously observed in this model. These distinct cellular signatures expand our understanding of how tau contributes to neurodegeneration and may inform more targeted therapeutic strategies based on predominant patterns of tau accumulation in different tauopathies.

Indexed as

A152Tglial cell profilingNanoStringoligomerP301Lsolubilitytauopathy

Identifiers

PMID40746858
PMCPMC12310919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.